Group 1 - PTC Inc. reported quarterly earnings of $1.79 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, and up from $1.46 per share a year ago, representing an earnings surprise of 29.71% [1] - The company posted revenues of $636.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.62% and increasing from $603.07 million year-over-year [2] - PTC Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates three times in the same period [2] Group 2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year compared to the S&P 500's decline of 5.5% [3] - The current consensus EPS estimate for the coming quarter is $1.46 on revenues of $623.14 million, and for the current fiscal year, it is $5.75 on revenues of $2.48 billion [7] - The Zacks Industry Rank for Computer - Software is in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - Qualcomm reported quarterly earnings of $2.85 per share, exceeding the Zacks Consensus Estimate of $2.83 per share, and showing an increase from $2.44 per share a year ago, indicating a positive earnings surprise of 0.71% [1][2] Financial Performance - The company achieved revenues of $10.84 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.55%, and up from $9.39 billion year-over-year [2] - Qualcomm has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Qualcomm shares have declined approximately 4.4% since the beginning of the year, while the S&P 500 has seen a decline of 5.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.65 on revenues of $10.29 billion, and for the current fiscal year, it is $11.85 on revenues of $43.39 billion [7] - The outlook for the Electronics - Semiconductors industry is positive, ranking in the top 23% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Etsy reported quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.50 per share, representing an earnings surprise of -8% [1]. Financial Performance - The company posted revenues of $651.18 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33% and showing a year-over-year increase from $645.95 million [2]. - Over the last four quarters, Etsy has surpassed consensus revenue estimates three times [2]. Stock Performance - Etsy shares have declined approximately 12.8% since the beginning of the year, compared to a decline of -5.5% for the S&P 500 [3]. - The current consensus EPS estimate for the upcoming quarter is $0.52 on revenues of $638.28 million, and for the current fiscal year, it is $2.60 on revenues of $2.77 billion [7]. Industry Outlook - The Internet - Commerce industry, to which Etsy belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]. - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Etsy's stock performance [5]. Future Expectations - The estimate revisions trend for Etsy is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]. - The upcoming earnings call will be crucial for assessing the sustainability of the stock's price movement based on management's commentary [3].

Company Performance - GeneDx Holdings Corp. reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and a significant improvement from a loss of $0.33 per share a year ago, representing an earnings surprise of 154.55% [1] - The company achieved revenues of $87.12 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.03%, and showing an increase from $62.42 million in the same quarter last year [2] - Over the last four quarters, GeneDx Holdings has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - GeneDx Holdings shares have increased approximately 52.2% since the beginning of the year, contrasting with a decline of -5.5% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $86.8 million, and for the current fiscal year, it is $0.97 on revenues of $359.7 million [7] Industry Outlook - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Insights - GSK reported quarterly earnings of $1.13 per share, exceeding the Zacks Consensus Estimate of $1.08 per share, and showing an increase from $1.09 per share a year ago, resulting in an earnings surprise of 4.63% [1] - The company posted revenues of $9.46 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.85%, but showing growth from $9.34 billion year-over-year [2] - GSK's stock has increased by approximately 15.2% since the beginning of the year, contrasting with a -5.5% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05, with projected revenues of $10.04 billion, and for the current fiscal year, the EPS estimate is $4.24 on revenues of $40.62 billion [7] - The estimate revisions trend for GSK is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which GSK belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1: Earnings Performance - TPG RE Finance Trust reported quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.26 per share, and down from $0.30 per share a year ago, representing an earnings surprise of -7.69% [1] - The company posted revenues of $37.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.56%, and down from $38.93 million year-over-year [2] - Over the last four quarters, TPG RE Finance Trust has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Group 2: Stock Performance and Outlook - TPG RE Finance Trust shares have declined approximately 12.8% since the beginning of the year, compared to a -6% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.25 on revenues of $37.52 million, and for the current fiscal year, it is $1.03 on revenues of $149.72 million [7] Group 3: Industry Context - The Real Estate - Operations industry, to which TPG RE Finance Trust belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TPG RE Finance Trust's stock performance [5][6]

Company Performance - LSB reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.12 per share a year ago, representing an earnings surprise of -200% [1] - The company posted revenues of $143.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.04%, and an increase from year-ago revenues of $138.2 million [2] - Over the last four quarters, LSB has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Stock Performance - LSB shares have declined approximately 22.4% since the beginning of the year, while the S&P 500 has decreased by 6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.23 on $154 million in revenues, and $0.27 on $551.05 million in revenues for the current fiscal year [7] Industry Outlook - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LSB's stock performance [5]

Core Insights - Centene (CNC) reported quarterly earnings of $2.90 per share, exceeding the Zacks Consensus Estimate of $2.36 per share, and up from $2.26 per share a year ago, representing an earnings surprise of 22.88% [1] - The company achieved revenues of $46.62 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.24% and increasing from $40.41 billion year-over-year [2] Earnings Performance - Over the last four quarters, Centene has surpassed consensus EPS estimates three times, indicating strong earnings performance [2] - The company also topped consensus revenue estimates four times in the last four quarters, showcasing consistent revenue growth [2] Stock Performance - Centene shares have increased approximately 1.7% since the beginning of the year, contrasting with the S&P 500's decline of -6.8% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.16 on revenues of $43.09 billion, while for the current fiscal year, the estimate is $7.13 on revenues of $172.83 billion [7] - The estimate revisions trend for Centene is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - HMOs industry, to which Centene belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Centene's stock performance [5]

Group 1 - Heritage Commerce (HTBK) reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.17 per share a year ago, resulting in an earnings surprise of 5.56% [1] - The company posted revenues of $46.06 million for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.31%, and an increase from $42.14 million year-over-year [2] - Over the last four quarters, Heritage Commerce has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Group 2 - The stock's immediate price movement will largely depend on management's commentary during the earnings call, with shares down approximately 3.3% year-to-date compared to the S&P 500's decline of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $47.13 million, and for the current fiscal year, it is $0.80 on revenues of $191.47 million [7] - The Zacks Industry Rank for Banks - West is in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago. These figures are adju ...